Simulations Plus to work with FDA on mechanistic IVIVC modeling

Simulations Plus, Inc. (NASDAQ: SLP) said it has signed a five-year research collaboration agreement with the US Food and Drug Administration to work together to determine the value of mechanistic absorption modeling in developing predictive and robust in vitro-in vivo correlations.

The collaboration will examine how the use of MAM can provide additional insight and greater accuracy with regards to prediction of complex drug absorption characteristics. The ultimate goal is to facilitate drug and generic product development by decreasing the regulatory burden through adequate modeling approaches.

Under the agreement, Simulations Plus will provide licenses for the company´s GastroPlus simulation software to model in vivo data representative of challenging absorption characteristics to the FDA´s Office of Testing and Research located in the Center for Drug Evaluation and Research Office of Pharmaceutical Science.

0saves
If you enjoyed this post, please consider leaving a comment or subscribing to the RSS feed to have future articles delivered to your feed reader.

Comments are closed.

Powered by WordPress